Cytokinetics, Incorporated (CYTK)
Summary
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy
Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.
Cytokinetics, Incorporated Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 187 | $7,958.23 | $15,368.59 | $7,410.36 | 93.12% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 200 | $12,708 | $16,437 | $3,729 | 29.34% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 12 | $786.18 | $984.48 | $198.3 | 25.22% |
| BG Bart Gancher Intech Investment Management LLC | 53,348 | $2.67M | $4.38M | $1.71M | 64.12% |
 Anthony Scaramucci SkyBridge Capital II LLC | 764,538 | $35.31M | $62.62M | $27.31M | 77.33% |
Cytokinetics, Incorporated Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JH Jeffrey Hung Morgan Stanley | 538.56 | $24,196.2 | $43,278.76 | $19,082.56 | 78.87% |
| AV Ashwani Verma UBS | 57.66 | $5,031.47 | $4,619.2 | -$412.27 | -8.19% |
 Salim Syed Mizuho | 290.95 | $19,032.37 | $23,380.86 | $4,348.49 | 22.85% |
Cytokinetics, Incorporated (CYTK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cytokinetics, Incorporated ever had a stock split?
Cytokinetics, Incorporated Profile
| Biotechnology Industry | Healthcare Sector | Robert I. Blum CEO | NASDAQ (NGS) Exchange | 23282W605 CUSIP |
| US Country | 673 Employees | - Last Dividend | 25 Jun 2013 Last Split | 29 Apr 2004 IPO Date |
Overview
Cytokinetics, Incorporated is a distinguished late-stage biopharmaceutical organization deeply engaged in the meticulous discovery, development, and upcoming commercialization of novel muscle activators and inhibitors as potent therapeutic interventions for severe and debilitating diseases. With its foundation year pegged at 1997 and nestled in the bustling hub of South San Francisco, California, this entity dedicates itself to forging advancements in medical science, particularly within the realm of muscle function and contractility. This endeavor is marked by the synthesis of small molecule drug candidates, meticulously engineered to modify muscle dynamics. In alliance with Ji Xing Pharmaceuticals Limited, Cytokinetics is at the forefront of crafting solutions aimed at addressing the pressing needs within the healthcare landscape.
Products and Services
- Omecamtiv Mecarbil
- CK-136
- CK-586
- Aficamten
A cutting-edge and novel cardiac myosin activator, Omecamtiv Mecarbil stands as a prototype in Phase III clinical trial, primarily focusing on patients plagued with heart failure. This drug candidate embodies Cytokinetics' commitment to innovation in cardiac care, aiming to enhance the contractile function of the heart muscle, thereby potentially offering a new lease of life to those suffering from this debilitating condition.
Currently undergoing scrutiny in Phase I clinical trial, CK-136 emerges as a novel cardiac troponin activator. This investigative entity is crafted to fine-tune the heart's muscle contraction process, indicating a groundbreaking approach towards ameliorating cardiac function. By activating cardiac troponin, CK-136 opens up new vistas in the treatment paradigms of heart diseases, heralding a promising venture into improving heart health.
CK-586 represents a pioneering small molecule cardiac myosin inhibitor, orchestrating its journey through Phase I clinical trials. This therapeutic candidate is conceived to temper down the contractile force of the heart's muscles, offering a novel pathway for managing conditions characterized by excessive cardiac contractility. Its development aligns with Cytokinetics’ broader vision of introducing therapies that can meticulously modulate heart muscle function for the better.
Embarking on its Phase III clinical trial, Aficamten is unveiled as a groundbreaking cardiac myosin inhibitor geared towards treating patients grappling with symptomatic obstructive hypertrophic cardiomyopathy. This therapeutic avenue exemplifies a strategic bid to counteract the challenges posed by this heart condition, utilizing a mechanism aimed at reducing myocardial contractility, hence alleviating the symptoms and improving life quality for affected individuals.
